Allarity Therapeutics settled a $4.9 million liability owed to Novartis Pharma AG for $1 million, releasing both parties from claims under a previously terminated license agreement. The company also announced its first revenue-generating commercial agreement under its newly established CLIA-certified laboratory services strategy, providing development and validation services for a European biotechnology company's precision oncology device. Allarity Therapeutics is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments.
